Get the full picture
Sign in to uncover key details.
Seed Therapeutics
Business Services · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
411 Swedeland Rd Ste 1000, King of Pruss...Phone Number
(646) 305-6387Website
www.seedtherapeutics.comRevenue
$5.3 MillionIndustry
About Seed Therapeutics
SEED Therapeutics specializes in designing molecular glue degraders that utilize the full E3 ligase universe to target and eliminate disease proteins, particularly in oncology. Their innovative RITE3 platform enables the identification of optimal ligase-target pairs, allowing for a more precise approach to targeted protein degradation. The company is currently advancing its lead product, ST-01156, through Phase 1 trials for various tumors, supported by strategic partnerships with industry leaders like Lilly and Eisai. SEED Therapeutics aims to make a significant impact on patient care by developing therapies for diseases where traditional treatments have failed.Explore more
Seed Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Seed Therapeutics
Compare insights from companies similar to Seed Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Seed Therapeutics Tech Stack
A closer look at the technologies used by Seed Therapeutics
See more technologies
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Seed Therapeutics
Sign Up For FreeTo access detailed company insights
SEED Therapeutics specializes in designing molecular glue degraders that utilize the full E3 ligase universe to target and eliminate disease proteins, particularly in oncology. Their innovative RITE3 platform enables the identification of optimal ligase-target pairs, allowing for a more precise approach to targeted protein degradation. The company... Read More
